tbuckley/cabot-search huggingface dataset:
HIDEYO NOGUCHI—THE TEMPESTUOUS MICROBIOLOGIST
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Frequent clonal proliferation of human T-cell leukemia virus type 1 (HTLV-1)-infected T cells in HTLV-1-associated myelopathy (HAM-TSP)
Authors: Y Furukawa, J Fujisawa, M Osame, M Toita, S Sonoda, R Kubota, S Ijichi, M Yoshida
Journal: Blood (1992)
Malignant pyoderma
Authors: J. A. R. ANDERSON
Journal: British Journal of Dermatology (1978)

A patient is described who developed multiple areas of inflammatory pyoderma on the face, leading to extensive ulceration. Repeated investigations failed to demonstrate any specific bacteria or fungus responsible and trials of treatment with various antibiotics proved unsuccessful. Histology revealed a granulomatous abscess‐like lesion, and the condition resembled what has been described as malignant pyoderma. The patient was successfully treated with oral dapsone and intralesional steroids.
Ongoing outbreak of visceral leishmaniasis in Bologna Province, Italy, November 2012 to May 2013
Authors: S Varani, R Cagarelli, F Melchionda, L Attard, C Salvadori, AC Finarelli, GA Gentilomi, R Tigani, R Rangoni, R Todeschini, A Scalone, T Di Muccio, M Gramiccia, L Gradoni, P Viale, MP Landini
Journal: Eurosurveillance (2013)

An increased number of autochthonous visceral leishmaniasis (VL) cases has recently been reported in Bologna Province in northern Italy. Over six months from November 2012 to May 2013, 14 cases occurred, whereas the average number of cases per year was 2.6 (range: 0-8) in 2008 to 2012. VL was diagnosed in a median of 40 days (range: 15-120) from disease onset. This delay in diagnosis shows the need for heightened awareness of clinicians for autochthonous VL in Europe. .
Illustrations of Exceptional Symptoms and Examples of Rare Forms of Disease
Authors: J. Hutchinson
Journal: BMJ (1886)

s account of her symptoms was very interesting.Sle said Athatbe-had, forthree years, been liable to periods of6chilliness, dutring VWhits she could not keep warm.Nothihi.g*arfmedher;^neither exern 6se ior ire-heat ;-the nearest approach"to warmth being obtained in ted.After two or three days, the ataeck -ould end by ia blush of tedness appeaTing across the forehead.When thi$ came, tle-chilliness 44vwaysceased.Puring these attacks, she does not usuallyfeel ill, but take her food almost as usual.Recently, that-is, during the last six months, the attacks, which have recurred almost monthly, have been 1attended by swelling of the eyelids.The lids, wben I saw Mrs. B., *ere still somewhat swollen, the lower ones especially, and the con- dition of solid cedema of the lids was clearly thre4tened.Her ears -*lso had of late become swollen and red during the attacks.Thus it seems probable that the attacks of chilliness was really a modified fform of rigor preceding slight attacks of recurrent erysipelas.It is "remarkable that they should be so prolonged ari attended by so little -disturbance of health, and followed by such very slight erysipelatous redness.Still the gradual increase of the local change,, and the pro- 'nction of cedema, seem to definitely place the attacks in this category.Another explanktion is, however, possible, and iti is that the attacks 'atre indicative of liver-disturbance.Mrs. B. has large patches of xantlie- lasw6a on her upper eyelids,' the largest being, contrary to rule, on the :Aght side.She -has known of these for two years or more.She is also 'liable to a'ttacks of dizziness and dimness before her eyes.Mrs. B. is '42 years of age, of a phlegmatic temperament.She says that she can- not exist without fresh air, and is accustomed to sit in a draught of 'wind whenever she can.
Erratum: Inv(11)(q21q23) fuses MLL to the Notch co-activator mastermind-like 2 in secondary T-cell acute lymphoblastic leukemia
Authors: M Metzler, M S Staege, L Harder, D Mendelova, J Zuna, E Fronkova, C Meyer, T Flohr, D Bednarova, J Harbott, T Langer, S Gesk, J Trka, R Siebert, T Dingermann, R Marschalek, C Niemeyer, W Rascher
Journal: Leukemia (2008)
The utility of PET scanning in colorectal cancer liver metastases being considered for surgery.
Authors: Ciara Marie Kelly, Lauragh McCarthy, Aine O'Reilly, Peter McEneaney, Michael William Bennett, Kevin N. O'Regan, Erica Mulvihill, Adrian O'Sullivan, Criostoir O Suilleabhain, Seamus O'Reilly, Derek G. Power
Journal: Journal of Clinical Oncology (2013)

561 Background: Liver resection remains the only potentially curative option for a subset of patients with metastatic colorectal cancer (CRC) to liver. Preoperative imaging used to determine resectability includes contrast enhanced computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET). The objective of this study was to determine the utility of PET scanning for potentially resectable metastatic CRC to liver. Methods: We retrospectively reviewed a prospectively maintained database for all patients considered for liver resection of metastatic CRC from July 2010 to July 2012 in a specialist colorectal/hepatobiliary cancer centre. We extracted and analysed data with respect to preoperative staging imaging and definitive treatment performed on completion of staging. Results: We identified 50 patients who underwent preoperative staging investigations for potentially resectable metastatic CRC to liver. The imaging techniques performed included: CT (n=50, 100%), MRI liver (n=45, 90%), PET (n= 47, 94%). In 9 (9/47, 19%) patients PET scanning added to the preoperative cross sectional staging information, identifying local recurrence (n=1, 2%), confirming liver metastases following an inconclusive CT/MRI (n=1, 2%), and identifying extrahepatic sites suspicious for disease (n=7, 15%). The extrahepatic sites included either lung (n=4) or bone (n=1) or lymph nodes (n=2). One patient with FDG-avid mediastinal lymph nodes had no cancer on endobronchial biopsy. PET scanning definitively changed the therapeutic strategy in 6 patients (6/47, 12.8%): precluding liver resection in 2 patients (2/47, 4.3%), leading to resection of extrahepatic disease in 3 patients (3/47, 6.4%) and resection of hepatic metastases in one patient (1/47, 2.1%). Conclusions: In this small retrospective cohort the addition of metabolic imaging changed the management in 12.8% of patients with potentially resectable liver confined metastatic CRC. We plan to include data from other cancer centres in Ireland to confirm our findings.
Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of <i>RAS</i> wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study.
Authors: Sebastian Stintzing, Ilse van Oostrum, Chris Pescott, Alma Katharina Steinbach-Buechert, Bart Heeg, Volker Heinemann
Journal: Journal of Clinical Oncology (2018)

e15711 Background: The randomized, phase 3 FIRE-3 trial evaluated first-line (1L) FOLFIRI + cetuximab (cet) vs FOLFIRI + bevacizumab (bev) in patients (pts) with RAS wt mCRC; overall survival favored FOLFIRI + cet by > 8 months. The purpose of this analysis was to evaluate the cost-effectiveness of FOLFIRI + cet vs that of FOLFIRI + bev as 1L treatment for pts in Germany with RAS wt mCRC. Two independent subgroup analyses were conducted, one for pts with left-sided (LS), RAS wt primary tumors and another for pts with liver limited disease (LLD). Methods: A standard oncology 3–health-state partitioned survival cost-utility model was developed to analyze the costs and health effects of FOLFIRI + cet vs those of FOLFIRI + bev from a German payer perspective based on data from FIRE-3 and the literature. Health outcomes were reported in life-years (LYs) and quality-adjusted life-years (QALYs). A 3.5% discounting rate was applied to the modeled costs and outcomes. Results: Costs, effects, and incremental cost-effectiveness ratios (ICERs) for pts with RAS wt (base case), LS tumors, and LLD are summarized in the Table. Probabilistic sensitivity analyses showed that at relevant European willingness-to-pay (WTP) thresholds of €55,000 and €80,000, FOLFIRI + cet had a 64.0% and 81.6% (base case), 80.5% and 92.4% (LS tumors), and 89.9% and 93.8% (LLD) probability of being cost-effective vs FOLFIRI + bev, respectively. Conclusions: Based on our analyses, FOLFIRI + cet is cost-effective compared with FOLFIRI + bev in pts treated in Germany with RAS wt mCRC. The cost-effectiveness of FOLFIRI + cet improves for subgroups with LS tumors, or LLD. Treatment Costs LYs QALYs ICER (cost per LY gained) ICER (cost per QALY gained) Base case: RAS wt FOLFIRI + cet €89,434 3.04 2.18 €32,370 €46,712 FOLFIRI + bev €69,138 2.41 1.75 Increment €20,297 0.63 0.43 LS tumors FOLFIRI + cet €91,088 3.46 2.48 €23,736 €34,114 FOLFIRI + bev €69,216 2.54 1.84 Increment €21,873 0.92 0.64 LLD FOLFIRI + cet € 97,543 4.20 2.99 € 13,154 € 18,970 FOLFIRI + bev € 77,695 2.69 1.95 Increment € 19,848 1.51 1.05
THERMOREGULATION OF REFRIGERATORS
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DOMESTIC CORRESPONDENCE.
Authors: F. LOHRSTORFER
Journal: JAMA (1892)

<h3>To the Editor of the Journal of the American Medical Association:</h3> Please give publicity through yourJournalto a confidence game that is being worked on physicians in this State and probably in others. A "special agent" sailing under the name of F. C. Washburn, of St. Paul, Minn., goes from city to city appointing medical examiners for the Bankers' Mutual Aid Association of St. Paul, Minn. The examiner is naturally requested to take a policy for which he pays $5.00 quarterly dues in advance. No policy ever appears and the appointment is bogus. Yours very truly, Port Huron, Mich., Oct. 8, 1892.
Book Reviews
Authors: Giovanni A. Fava, George N. Christodoulou, Thalia G. Dragonas, B. Van Houdenhove, D. Verstraeten, P. Onghena, H. De Cuyper, Jambur Ananth, Lee S. Mann, Thomas N. Wise, Laurel Shay
Journal: Psychotherapy and Psychosomatics (1992)
Diagnostic Tests for Silicone Breast Disease
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Just Talk
Authors: Ronald H. Lands
Journal: Annals of Internal Medicine (2011)

Ad Libitum5 July 2011Just TalkRonald H. Lands, MDRonald H. Lands, MDFrom University of Tennessee, Knoxville, TN 37924.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-155-1-201107050-00012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Talk to her like she can hear you,they say, ‘though I doubtthat any of them has ever seenthat one in a million casewhere someone woke from a comaand described the pearly gates.It's surprising, they say,what people remember ...needle sticksclaustrophobia in the CT scannermean night shift nursesoverheard conversations between the kidsabout when daddy came homewith nothing left of his paycheckfrom the job he hated so muchhe had to drink to keep working.Just talk to her, they say,as if someone is listening.Ronald H. Lands, MDUniversity of TennesseeKnoxville, TN 37924 Author, Article, and Disclosure InformationAffiliations: From University of Tennessee, Knoxville, TN 37924.Current Author Address: Ronald H. Lands, MD, Department of Medicine, University of Tennessee, 1924 Alcoa Highway, Knoxville, TN 37924. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 5 July 2011Volume 155, Issue 1Page: 64KeywordsComaComputed axial tomography ePublished: 5 July 2011 Issue Published: 5 July 2011 Copyright & PermissionsCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
index to advertisers
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THU0364 Lower Etanercept Levels are Associated with High Disease Activity in Ankylosing Spondylitis Patients at 24 Weeks of Follow-Up
Authors: E. L. Kneepkens, C. L. Krieckaert, M. T. Nurmohamed, I. E. van der Horst-Bruinsma, G. J. Wolbink
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Etanercept levels are associated with clinical response in rheumatoid arthritis, however, in a small group of 53 patients with ankylosing spondylitis (AS) this association was not found (de Vries MK et al. ARD 2009). <h3>Objectives</h3> To investigate the relationship between etanercept levels and clinical response in a large cohort of AS patients. <h3>Methods</h3> Prospective observational cohort study of 170 consecutive AS patients treated with etanercept, monitored during 24 weeks of follow-up. Etanercept trough levels were determined retrospectively using an enzyme linked immunosorbent assay (ELISA) designed by Sanquin Research, Amsterdam. Response to etanercept treatment was defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) response (50% improvement or an absolute improvement of 2 points on a BASDAI, scale 0-10) and disease activity was measured using AS Disease Activity Score, including CRP (ASDAS). <h3>Results</h3> Of 170 patients, 122 (71.8%) were male and 130 (82.8%) were HLA-B27 positive. At baseline median BASDAI was 6.0 (IQR 4.8-7.1) and mean ASDAS was 3.5 (SD 1.0). After 24 weeks 98 (57.6%) patients were BASDAI responder (last observation carried forward), mean ASDAS (SD) for responders was 1.6 (0.9) vs. 2.4 (0.9) for non-responders (p&lt;0.001). Of 170 patients 19 dropped out: 16 (84.2%) due to treatment failure or adverse events and 3 (15.8%) due to other reasons. At 24 weeks of treatment etanercept levels were significantly higher in patients with inactive to moderate disease activity (ASDAS &lt;2.1, median (IQR) 3.7 (2.5-5.5)) compared to patients with high to very high disease activity (ASDAS ≥2.1, (median (IQR) 2.3 (1.2-3.7)) (p=0.01). For BASDAI response no significant association with etanercept levels was found. When patients were categorized into quartiles according to the height of etanercept levels at 24 weeks, the lowest quartile (etanercept level &lt; 1.8 mg/L) comprised 35.1% of all patients with ASDAS ≥2.1. The highest quartile (etanercept level &gt; 5.0 mg/L) comprised 33.8% of all patients with ASDAS &lt;2.1. <h3>Image/graph</h3> <h3>Conclusions</h3> Lower etanercept levels in AS are associated with high disease activity at 24 weeks of treatment. <h3>Disclosure of Interest</h3> E. Kneepkens: None Declared, C. Krieckaert: None Declared, M. Nurmohamed Grant/research support from: Abbott, Roche, Pfizer, Consultant for: Abbott, Roche, Pfizer, MSD, UCB, SOBI and BMS, Speakers bureau: Abbott, Roche, Pfizer, I. van der Horst-Bruinsma: None Declared, G. Wolbink Grant/research support from: Pfizer, Speakers bureau: Pfizer, Amgen
Introduction to the Histology and Histopathology of the Nervous System.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Geirangerfjord, Norway
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract 341: Disturbance of p53-indcued Long Noncoding RNA Meg3 - FUS Complex by AAV9 System Preserves Heart Function in Myocardial Infarction
Authors: Hongchun Wu, Kaili Hao, You Yu, Xinglong Han, Jingjing Li, Zhen-Ao Zhao, Junwei Liu, Joseph C Wu, Shijun Hu
Journal: Circulation Research (2017)

Introduction: The injured heart undergoes a major process of cellular apoptosis in the initial stage of MI, therefore, the most fundamental method to prevent post-MI remodeling is to suppress cardiomyocyte apoptosis. In this study, we have illustrated the key role of long noncoding RNA, Maternally expressed gene 3 ( Meg3 ), on cardiomyocyte apoptosis and the underlying mechanisms in heart. Methods: Neonatal murine cardiomyocytes and human ESC-derived cardiomyocytes were subjected to hypoxia, and cellular apoptosis was evaluated with Annexin V assay. The Meg3 regulation by p53 was measured by luciferase reporter assay. The complex of Meg3 and RNA-binding protein FUS (Fused in sarcoma) was determined by EMSA and RIP. Adeno-Associated Virus serotype 9 (AAV9) system was employed to knock down Meg3 in cardiomyocytes in vivo, and the cardiac function was evaluated by echocardiography and ex-vivo assays. Results: We first found that Meg3 was progressively upregulated in the murine injured heart after MI, and it showed the pro-apoptotic functions in primary cardiomyocytes. Meg3 could be directly upregulated by p53 during hypoxia condition, and was involved in apoptotic regulation via its direct binding with FUS. The Meg3 knockdown in cardiomyocytes by AAV9 system could preserve heart function in murine myocardial infarction. Moreover, its pro-apoptotic function was conserved in human cardiomyocytes. Conclusion: Together, these results indicate that p53-induced Meg3 - FUS complex plays an important role on cardiomyocyte apoptosis post-MI, and its specific knockdown in cardiomyocytes with AAV9 system represents a promising method to treat myocardial infarction.